Buradasınız

Anasayfa » Content

FÎSTÜL TROMBOZU GELÎŞMÎŞ OLAN HEMODİYALİZ HASTALARINDA ANTİKARDİYOLİPİN ANTİKORLARIN KLİNİK ÖNEMİ

CLINICAL IMPORTANCE OF ANTIPHOSPHOLIPID ANTIBODIES IN HEMODIALYSIS PATIENTS WITH VASCULAR ACCESS THROMBOSIS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Antiphospholipid antibodies can cause recurrent thrombotic attacks in some patients. Antiphospholipid antibodies are detected in patients with autoimmune disease especially systemic lupus erythematosus, infectious, malignant and drug-induced disorders. Vascular access-related complications are an important cause of morbidity. Antiphospholipid antibodies have been involved in thrombosis, and have been reported to be present in a high proportion of patients with chronic renal failure We studied the prevalence of anticardiolipin antibodies and vasculer access thrombosis among patients undergoing haemodialysis. ACA were measured in 18patients (10 man, 8 women) have no Vascular access thrombosis and 17 patients (10 women, 7 man) have recurrent Vascular access thrombosis . ACA was measured by a ELİ S A method. ACL Ig G was found as positive in 2 patients (%11.1) with have no vascular access thrombosis and was detected in one patient (%5.8) with vascular access thrombosis. ACL Ig M were found to be negative in all patients. Consequently, we concluded that no increase was detected in ACA existence in hemodialysis patients who developed thrombosis.
Bookmark/Search this post with
Abstract (Original Language): 
Sistemik lupus eritematozus ve bir çok kollajen doku hastalığında, infeksiyonlarda, malignitelerde ve çeşitli ilaçların kullanımında pozitif olabilen anti kardiyolipin antikorların (AKA) varlığında tekrarlayıcı trombozlara sık rastlanılmaktadır. Arteriyovenöz fistiil (AVF) trombozlannın, hastaneye yatış nedenleri arasında önemli bir yer tuttuğu son dönem böbrek yetmezlikti hastalarda AKA 'ların arttığına ilişkin yayınlar bulunmaktadır. Son dönem böbrek yetmezlikli hastalardan geç dönemde AVF trombozıt gelişmiş 17 (10 erkek, 7kadın) ve A VF trombozu gelişmemiş 18 (10 erkek, 8 kadın) hastada AKA 'ların varlığı araştırıldı. Bulgular Fisher exact x testi ile yorumlandı. Tromboz gelişmiş olan hastalardan birisinde (%5.8), tromboz gelişmemiş hastalardan ikisinde AKApozitifliği vardı. Aralarında istatistiksel anlamlı fark yoktu (p=0.603). Son dönem böbrek yetmezlikli hastalarda total olarak üç hastada AKA pozitifliği varken, kontrol grubunda AKA pozitifliğine rastlanmadı. Ancak istatistiksel olarak anlamlı farklılık bulunmadı (p=0.293) Sonuç olarak fistiil trombozu gelişmiş hemodiyaliz hastalarında AKA varlığında artış tesbit edilmemiştir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_320.pdf
  • 1
34-36
  • Turkish

REFERENCES

References: 

1. Fabrizi F, Sangiorgio R, Pontoriero G, Corti M, Tentem
F. Antiphospholipid (aPL)
antibodie
s in end-stage renal disease. J Nephrol 1999;12:89-94.
2. Prakash R, Miller CC, Suki WN. Antieardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995;26:347-52.
3. Sallam S, Wafa E, el-Gayar A, Sobh M, Salama O
Anticardiolipin antibodies in children on chronic haemodialysis. Nephrol Dial Transplant 1994,9:1292¬94.
4. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis
patients. Kidney Int 1999 ;55:315-2O.
5. Sitter T, Schiffl H. Anticardiolipin antibodies in patients on regular hemodialysis: an epiphenomenon?
Nephron 1993;64:655-56.
6. Jones JV, Eastwood BJ, Jones E, James H, Mansour M. Antiphospholipid antibodies in a healthy population: methods for estimating the distrubution. J Rheumatol 1995;22:55-61.
7. Fields RA.Toubbeh H, Searles RP, Bankhurst AD. The
prevalence of anticardiolipin antibodies in healthy elderly population and its association with antinuclear
antibodies. J Rheumatol 1989;16:623-25.
8. Munoz-Rodriguez FJ, Tassies D, Font J, Reverter JC, Cervera R. Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol 1999;30:770-733.
9. Buchanan RR, Wardlaw JR, Riglar AG, Littlejohn GO,
Miller MH Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J
Rheumatol 1989;16:757-61.

Thank you for copying data from http://www.arastirmax.com